Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GPX4 | P36969 | 3/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986720 | 0.89 | PDE4D (0.44) | PDE4DPDE4APDE4BPDE4CUTS2R | |
| SCHEMBL986982 | 0.88 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CUTS2R | |
| SCHEMBL1009756 | 0.87 | PDE4D (0.53) | PDE4DDHFRMAPTALDH1A1KDM4E | |
| SCHEMBL8006958 | 0.81 | PDE4D (0.50) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL984917 | 0.76 | PDE4D (0.57) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL3117592 | 0.67 | MAPT (0.58) | DHFRMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL2227760 | 0.67 | ALDH1A1 (0.56) | DHFRMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL6413627 | 0.67 | UTS2R (0.57) | UTS2R | |
| SCHEMBL8211561 | 0.66 | TAAR1 (0.51) | — | |
| SCHEMBL1157410 | 0.65 | C5AR1 (0.46) | PDE4DPDE4APDE4BPDE4CDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247294-B1 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | BASILEA PHARMACEUTICA AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| EP-2247294-A2 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | Basilea Pharmaceutica AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009098320-A2 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | PDE4D 2679/4885PDE4A 1873/4885PDE4B 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.